Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propafenone
Drug ID BADD_D01856
Description An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Indications and Usage Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Marketing Status approved
ATC Code C01BC03
DrugBank ID DB01182
KEGG ID D08435
MeSH ID D011405
PubChem ID 4932
TTD Drug ID D0J2KV
NDC Product Code 51407-478; 24979-086; 69680-130; 69680-131; 71205-942; 12598-6285; 71205-941; 24979-087; 24979-085; 51407-477; 71205-940; 69680-132; 51407-479
UNII 68IQX3T69U
Synonyms Propafenone | Propafenone Hydrochloride, (R)-Isomer | Rytmo-Puren | Rytmogenat | SA-79 | SA 79 | SA79 | Propafenone, (+-)-Isomer | Propafenone, (R)-Isomer | Propafenone, (S)-Isomer | Propamerck | Apo-Propafenone | Baxarytmon | Cuxafenon | Fenoprain | Jutanorm | Nistaken | Prolecofen | Propafenon AL | Propafenon Hexal | Propafenone Hydrochloride | Hydrochloride, Propafenone | Propafenone Hydrochloride, (S)-Isomer | Rythmol | Propafenon Minden | Norfenon | Pintoform | Rytmonorm | Arythmol
Chemical Information
Molecular Formula C21H27NO3
CAS Registry Number 54063-53-5
SMILES CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lactic acidosis14.01.01.0020.000418%Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.000418%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.004055%Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.0030.001547%
Mania19.16.02.002--
Melaena24.07.02.013; 07.12.02.004--Not Available
Menopausal symptoms21.02.02.002--Not Available
Metabolic acidosis14.01.01.0030.003135%Not Available
Miosis06.05.03.003; 17.02.11.002--Not Available
Monocyte count increased13.01.06.009--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.0040.001045%
Muscular weakness17.05.03.005; 15.05.06.0010.000418%
Myalgia15.05.02.0010.000418%
Myocardial infarction24.04.04.009; 02.02.02.0070.000418%
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Neoplasm malignant16.16.01.0010.000418%Not Available
Nephrotic syndrome20.05.01.002--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurosis19.06.01.001--Not Available
Neutrophil count decreased13.01.06.010--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene